The historical rank and industry rank for Amarin's OCF Margin % or its related term are showing as below:
STU:EH3'
s OCF Margin % Range Over the Past 10 Years
Min: -55.21 Med: -12.49 Max: 3.15
Current: 11.88
During the past 13 years, the highest OCF Margin % of Amarin was 3.15%. The lowest was -55.21%. And the median was -12.49%.
STU:EH3's OCF Margin % is ranked better than 56.69% of 956
companies
in the Drug Manufacturers industry
Industry Median: 9.985
vs STU:EH3: 11.88
Amarin OCF Margin % Related Terms
Amarin OCF Margin % Historical Data
* Premium members only.
The historical data trend for Amarin's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:EH3 vs SCLX, MIRA, NSRX: OCF Margin % Comparison
For the Drug Manufacturers - General subindustry, Amarin's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amarin OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amarin's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Amarin's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amarin (STU:EH3) has a OCF Margin % of 14.16% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Amarin and its competitors. According to the industry distribution chart, Amarin ranks #414 out of 956 companies in the Drug Manufacturers industry, placing it in the top 43.3%.
Is Amarin's OCF Margin % too high?
Amarin's current OCF Margin % is 14.16%. The Drug Manufacturers industry median OCF Margin % is 9.99. Amarin's value of 14.16% is 41.8% above this industry median. Based on the distribution chart, Amarin ranks #414 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Amarin has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Amarin's OCF Margin % compare to SCLX and MIRA?
According to the Drug Manufacturers industry distribution chart, Amarin ranks #414 out of 956 companies for OCF Margin %. This puts Amarin in the upper half of its industry. The industry median OCF Margin % is 9.99. Amarin's value of 14.16% is 41.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.99, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amarin's current OCF Margin % of 14.16% is 41.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Amarin and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amarin's current OCF Margin % is 14.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amarin stock overvalued right now?
Amarin (STU:EH3) has a current OCF Margin % of 14.16%. The stock's GF Value™ is €10.41, compared to a current price of €13.90 — trading 33.5% above its estimated fair value. The current OCF Margin % is 14.16% and 41.8% above the Drug Manufacturers industry median of 9.99. Amarin's overall GF Score™ is 54/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Amarin (STU:EH3), the current OCF Margin % is 14.16% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amarin (STU:EH3) Overvalued in 2026?
Based on GuruFocus' analysis, Amarin stock appears to be overvalued.
The current stock price of €13.90 is trading 33.5% above its estimated GF Value™ of €10.41.
Key valuation signals for STU:EH3:
OCF Margin %: 14.16%
GF Value™: €10.41 vs. price of €13.90 (33.5% above fair value)
Industry Position: 41.8% above the Drug Manufacturers median (#414 of 956)
No single metric tells the full story. See the STU:EH3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.
54GF Score
Get the complete analysis for STU:EH3
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:EH3 has been successfully added to your 
